Coronavirus Disease 2019 (COVID-19) Mitigation Efforts and Testing During an In-Person Training Event—Uganda, 12–29 October 2020

Simple item page
dc.contributor.authorLaws, Rebecca L.
dc.contributor.authorBiraro, Sam
dc.contributor.authorKirungi, Wilford
dc.contributor.authorGianetti, Brittany
dc.contributor.authorAibo, Dorothy
dc.contributor.authorAwor, Anna C.
dc.contributor.authorWest, Christine
dc.contributor.authorSachathep, Karampreet K.
dc.contributor.authorKiyingi, Herbert
dc.contributor.authorWard, Jennifer
dc.contributor.authorMwangi, Christina
dc.contributor.authorNkurunziza, Peter
dc.date.accessioned2022-03-20T21:32:54Z
dc.date.available2022-03-20T21:32:54Z
dc.date.issued2021
dc.description.abstractViral load monitoring (VLM) to identify individuals failing antiretroviral therapy (ART) is not widely available in resource-limited settings. We compared the genotypic resistance patterns between clients with VLM versus immunological monitoring (IM).Between 2004–2008, 559 ART naïve clients were enrolled in a prospective cohort, initiated on ART, and monitored with viral load (VL) and CD4+ cell counts every 6 months (VLM group). From February 2008 through June 2009, 998 clients on ART for 36–40 months (corresponding to the follow-up time of the VLM group) at the same clinic and monitored with CD4+ cell counts every 6 months were recruited into a cross sectional study (IM group). Samples from VLM clients at 12, 24 and 36 months and IM clients at 36–40 months with VL > 2000 copies/ml underwent genotypic drug resistance testing.Baseline characteristics were similar. Virologic failure (VL > 400 copies/ml) at 12, 24 and 36 months in the VLM group were 12%, 6% and 8% respectively, and in the IM group 10% at 36–40 months. Samples from 39 VLM and 70 IM clients were genotyped. 23/39 (59%) clients in the VLM group (at 12, 24 or 36 months) compared to 63/70 (90%) in the IM group, (P < 0.0001) had at least 1 non-nucleoside reverse transcriptase mutation. 19/39 (49%) of VLM clients had an M184V mutation compared to 61/70 (87%) in the IM group (P < 0.0001). Only 2/39 (5%) of VLM clients developed thymidine analogue mutations compared to 34/70 (49%) of IM clients (P < 0.0001).Routine VL monitoring reduced the rate of accumulated genotypic resistance to commonly used ART in Uganda.en_US
dc.identifier.citationLaws, R. L., Biraro, S., Kirungi, W., Gianetti, B., Aibo, D., Awor, A. C., ... & Voetsch, A. C. (2021). Coronavirus Disease 2019 (COVID-19) Mitigation Efforts and Testing During an In-Person Training Event—Uganda, 12–29 October 2020. Clinical Infectious Diseases, 73(Supplement_1), S42-S44.https://doi.org/10.1186/1471-2334-12-381en_US
dc.identifier.issn1471-2334
dc.identifier.urihttps://nru.uncst.go.ug/xmlui/handle/123456789/2840
dc.language.isoenen_US
dc.publisherClinical Infectious Diseasesen_US
dc.titleCoronavirus Disease 2019 (COVID-19) Mitigation Efforts and Testing During an In-Person Training Event—Uganda, 12–29 October 2020en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Coronavirus Disease 2019 (COVID-19) Mitigation Efforts.pdf
Size:
146.75 KB
Format:
Adobe Portable Document Format
Description:
Coronavirus Disease 2019 (COVID-19) Mitigation Efforts and Testing During an In-Person Training Event—Uganda, 12–29 October 2020
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences